Avutometinib + defactinib

Medicare

Part D (self-administered)

Oral, self-administered, so it is a Part D drug: covered through a stand-alone Part D plan or Medicare Advantage drug benefit, usually on the specialty tier with 25 to 33% coinsurance until the annual cap ($2,000 in 2025, $2,100 in 2026). FDA accelerated approval May 2025 for KRAS-mutant low-grade serous ovarian cancer.

Commercial insurance

covered with prior authorisation

Covered for FDA-labelled and NCCN-listed uses, but almost always behind prior authorisation confirming diagnosis, biomarker and line of therapy; dispensed through a specialty pharmacy. KRAS mutation documented; a rare indication most plans review individually.

Part D out-of-pocket capped at $2,000 (2025) / $2,100 (2026). Medicare patients cannot use manufacturer co-pay cards; charity funds (PAN, HealthWell, CancerCare) and the Extra Help subsidy are the routes.

Sources: Medicare.gov: Drug coverage (Part D) · Medicare.gov: Costs for Medicare drug coverage (annual out-of-pocket cap). Not medical or financial advice; verify with your plan.

Notes

No UK marketing authorisation yet, so no NICE appraisal. Access only through a clinical trial or a company early access scheme.

NHS England

Not routinely funded

Sources: NICE search: avutometinib with defactinib. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.